CO6801719A2 - Forma cristalina de un inhibidor de la interacción de mdm2/4 y p53 - Google Patents

Forma cristalina de un inhibidor de la interacción de mdm2/4 y p53

Info

Publication number
CO6801719A2
CO6801719A2 CO13128275A CO13128275A CO6801719A2 CO 6801719 A2 CO6801719 A2 CO 6801719A2 CO 13128275 A CO13128275 A CO 13128275A CO 13128275 A CO13128275 A CO 13128275A CO 6801719 A2 CO6801719 A2 CO 6801719A2
Authority
CO
Colombia
Prior art keywords
mdm2
crystal form
interaction inhibitor
inhibitor
interaction
Prior art date
Application number
CO13128275A
Other languages
English (en)
Inventor
Joerg Berghausen
Haixia Ren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45093718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6801719(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6801719A2 publication Critical patent/CO6801719A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO13128275A 2010-11-19 2013-05-24 Forma cristalina de un inhibidor de la interacción de mdm2/4 y p53 CO6801719A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010078927 2010-11-19

Publications (1)

Publication Number Publication Date
CO6801719A2 true CO6801719A2 (es) 2013-11-29

Family

ID=45093718

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13128275A CO6801719A2 (es) 2010-11-19 2013-05-24 Forma cristalina de un inhibidor de la interacción de mdm2/4 y p53

Country Status (34)

Country Link
US (2) US9073898B2 (es)
EP (1) EP2640467B1 (es)
JP (1) JP5667308B2 (es)
KR (1) KR101561750B1 (es)
AR (1) AR083905A1 (es)
AU (1) AU2011331095B2 (es)
BR (1) BR112013011966A2 (es)
CA (1) CA2816810A1 (es)
CO (1) CO6801719A2 (es)
CU (1) CU24130B1 (es)
CY (1) CY1116002T1 (es)
DK (1) DK2640467T3 (es)
EC (1) ECSP13012628A (es)
ES (1) ES2528376T3 (es)
GT (1) GT201300132A (es)
HK (1) HK1184091A1 (es)
HR (1) HRP20150231T1 (es)
IL (1) IL226182A0 (es)
MA (1) MA34666B1 (es)
ME (1) ME02099B (es)
MX (1) MX336634B (es)
MY (1) MY160880A (es)
NZ (1) NZ610296A (es)
PE (1) PE20140420A1 (es)
PL (1) PL2640467T3 (es)
PT (1) PT2640467E (es)
RS (1) RS53770B1 (es)
RU (1) RU2013127661A (es)
SG (1) SG190186A1 (es)
SI (1) SI2640467T1 (es)
SM (1) SMT201500059B (es)
TW (1) TWI520950B (es)
WO (1) WO2012066095A1 (es)
ZA (1) ZA201303155B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 安定化させたp53ペプチドおよびその使用法
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP3004109A1 (en) 2013-05-27 2016-04-13 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
JP2016537384A (ja) 2013-11-21 2016-12-01 ノバルティス アーゲー ピロロピロロン誘導体およびbet阻害剤としてのその使用
CN105848656B (zh) * 2013-12-23 2019-10-25 诺华股份有限公司 药物组合
US20160339023A1 (en) * 2013-12-23 2016-11-24 Fang Li Pharmaceutical Combinations
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
WO2017037586A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Combination therapy using pi3k inhbitor and mdm2 inhibitor
RU2740091C2 (ru) 2015-08-28 2021-01-11 Новартис Аг Ингибиторы mdm2 и их комбинации
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
KR101838687B1 (ko) 2016-01-26 2018-03-15 한국생명공학연구원 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
SI3541387T1 (sl) 2016-11-15 2021-08-31 Novartis Ag Odmerek in režim za zaviralce interakcije HDM2-P53
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US11413284B2 (en) 2017-09-12 2022-08-16 Novartis Ag Protein kinase C inhibitors for treatment of uveal melanoma
EP3694518A1 (en) 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829420A (en) 1970-07-13 1974-08-13 Sumitomo Chemical Co 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
US4099002A (en) 1970-12-23 1978-07-04 Sumitomo Chemical Company, Limited Quinazolinone derivatives and a process for production thereof
JPS4822715B1 (es) 1970-12-28 1973-07-07
JPS5427356B2 (es) 1972-03-31 1979-09-10
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4258187A (en) 1977-06-16 1981-03-24 E. I. Du Pont De Nemours And Company Process for preparing quinazolinone oxides
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3420799A1 (de) 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
DE69233739D1 (de) 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
WO1998001467A2 (en) 1996-07-05 1998-01-15 Novartis Ag Inhibitors of the interaction between p53 and mdm2
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE938597T1 (de) 1996-09-06 2000-03-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
NZ335383A (en) 1996-11-18 2000-10-27 Biotechnolog Forschung Gmbh Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CA2350189A1 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
CA2355976C (en) 1998-12-22 2012-07-17 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ(adp−リボース)ポリメラーゼ阻害剤
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical MERGED PYRIMIDINE DERIVATIVE AND USE THEREOF
SI1663185T1 (sl) 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
US20080153791A1 (en) 2005-03-18 2008-06-26 Onpharm Gmbh 11Beta -Hydroxysteroid Dehydrogenases
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
US8367699B2 (en) 2006-09-15 2013-02-05 Nexuspharma, Inc. Tetrahydro-isoquinolines
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones

Also Published As

Publication number Publication date
MX336634B (es) 2016-01-26
EP2640467B1 (en) 2014-12-17
ZA201303155B (en) 2014-01-29
NZ610296A (en) 2014-08-29
ES2528376T3 (es) 2015-02-09
US20130245036A1 (en) 2013-09-19
ME02099B (me) 2016-02-20
ECSP13012628A (es) 2013-07-31
RS53770B1 (en) 2015-06-30
RU2013127661A (ru) 2014-12-27
MA34666B1 (fr) 2013-11-02
CU20120098A7 (es) 2012-10-15
BR112013011966A2 (pt) 2016-08-30
PT2640467E (pt) 2015-03-12
AU2011331095A1 (en) 2013-05-30
JP5667308B2 (ja) 2015-02-12
CA2816810A1 (en) 2012-05-24
PL2640467T3 (pl) 2015-05-29
MX2013005631A (es) 2013-07-05
SG190186A1 (en) 2013-06-28
US9073898B2 (en) 2015-07-07
EP2640467A1 (en) 2013-09-25
CY1116002T1 (el) 2017-04-26
WO2012066095A1 (en) 2012-05-24
HK1184091A1 (en) 2014-01-17
US8969351B2 (en) 2015-03-03
MY160880A (en) 2017-03-31
CU24130B1 (es) 2015-09-29
JP2013542968A (ja) 2013-11-28
TW201302725A (zh) 2013-01-16
TWI520950B (zh) 2016-02-11
DK2640467T3 (en) 2015-03-02
HRP20150231T1 (en) 2015-03-27
PE20140420A1 (es) 2014-04-02
AU2011331095B2 (en) 2016-03-10
US20120129871A1 (en) 2012-05-24
GT201300132A (es) 2014-06-09
KR101561750B1 (ko) 2015-10-19
AR083905A1 (es) 2013-04-10
SMT201500059B (it) 2015-05-05
SI2640467T1 (sl) 2015-04-30
KR20130087572A (ko) 2013-08-06
IL226182A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
CO6801719A2 (es) Forma cristalina de un inhibidor de la interacción de mdm2/4 y p53
SMT201600181B (it) Composti antiparassitari di diidroazolo e composizioni che li comprendono
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
DK3400944T3 (da) Ibat-inhibitorer til behandling af leversygdomme
SMT201500271B (it) Inibitori di neprilisina
BR112012017441A2 (pt) compostos e métodos
SMT201600272B (it) Diidropiridinoni e piperidinoni arilici come inibitori di mgat2
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
BR112013013663A2 (pt) ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
BR112012027165A2 (pt) composição e artigo
SMT201600127B (it) Forma cristallina di (r)-7-cloro-n-(chinuclidin- 3-il)benzo[b]tiofen-2-carbossamide cloridrato monoidrato
IT1404856B1 (it) Copricapo stirabile e suo procedimento di fabbricazione
BR112012028633A2 (pt) composição reticulada e artigo
DK2642992T3 (da) Forbindelser og anvendelse deraf
FI20106181A0 (fi) Menetelmä substraatin muodostamiseksi ja substraatti
BR112012021749A2 (pt) processos e compostos
IT1404249B1 (it) Parete di banchina e procedimento per la sua realizzazione
FR2955473B1 (fr) Structure de presentoir
BR112013012958A2 (pt) inibidores integrin ligado com quinase
ES1074944Y (es) Envase monodosis para dentifricos y similares
ITMI20100187U1 (it) Eurobox - portamonete -contamonete per 1 euro e 2 euro
FIU20114101U0 (fi) Seinäelementti ja seinärakenne
UA21308S (uk) Розгортка упаковки
UA21432S (uk) Розгортка упаковки

Legal Events

Date Code Title Description
FC Application refused